Posted by Michael Wonder on 03 Jun 2019
Galt Pharmaceuticals answers the call for better practices in pain management with a non-opioid therapeutic alternative
29 May 2019 - Officials with the FDA have given priority review designation to an opioid-free pain management treatment from Galt Pharmaceuticals.
According to the company, its supplemental abbreviated new drug application for the orphenadrine citrate, aspirin and caffeine combination (Orphengesic Forte), a muscle relaxant pain reliever, was given an August 2019 goal for approval.
